Sudeep Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case

June 24, 2026
Posted by: Kunal Singla
Category: News

The Sudeep Pharma share price target 2026 is Rs 1,000, implying approximately 20 percent upside from the current market price of Rs 837.8 (NSE: SUDEEPPHRM). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations tailwinds in focus, the Rs 1,000 price objective is supported by the FY27 earnings recovery thesis.

Sudeep Pharma (NSE: SUDEEPPHRM) is a Pharmaceutical Formulations company trading at Rs 837.8 with a market capitalisation of Rs 4,189 crore. Analysts have set the Sudeep Pharma share price target at Rs 1,000 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Table of Contents

Sudeep Pharma Share Price Target 2026: Key Takeaways

Sudeep Pharma share price target 2026: Rs 1,000 (20% upside from CMP Rs 837.8)
Bull case: Rs 1,200 | Bear case: Rs 670
Ticker: SUDEEPPHRM | Sector: Pharmaceutical Formulations | MCap: Rs 4,189 crore
52W range: Rs 581 to Rs 1,376 | PE: 25x
Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
Key risk: FY27 earnings miss or FII outflows from Indian equities

Sudeep Pharma Company Overview

Sudeep Pharma (NSE: SUDEEPPHRM) is a pharmaceutical formulations company listed in 2025 manufacturing tablets, capsules, and injectables for domestic and regulated export markets with an integrated facility in Gujarat. At CMP Rs 837.8 against a 52 week range of Rs 581 to Rs 1,376, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 4,189 crore with trailing PE of 25x. Compared to peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals, Sudeep Pharma is positioned as a potential re-rating candidate toward the Rs 1,000 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	SUDEEPPHRM
Sector	Pharmaceutical Formulations
CMP (2026)	Rs 837.8
52 Week High	Rs 1,376
52 Week Low	Rs 581
Market Cap	Rs 4,189 crore
Trailing PE	25x
12-Month Analyst Target	Rs 1,000
Bull Case Target	Rs 1,200
Bear Case Target	Rs 670

Why Is the Sudeep Pharma Share Price Target Set at Rs 1,000 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Sudeep Pharma share price target of Rs 1,000 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 837.8.

Structural Sector Tailwinds in Pharmaceutical Formulations

The Pharmaceutical Formulations sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Sudeep Pharma’s position among peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 1,200 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Sudeep Pharma’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,000 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Sudeep Pharma’s Pharmaceutical Formulations operations, improving the probability of achieving the Rs 1,000 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, Sudeep Pharma is positioned as a beneficiary of institutional reallocation toward the Rs 1,200 bull case over the medium term.

Sudeep Pharma Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Sudeep Pharma Share Price Target

Near-term support for Sudeep Pharma is anchored close to the 52 week low of Rs 581. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 837.8.

12-Month Sudeep Pharma Share Price Target 2026

The 12-month Sudeep Pharma share price target 2026 is Rs 1,000, implying approximately 20 percent upside from CMP Rs 837.8. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term Sudeep Pharma Share Price Target: FY27 to FY28

The long term Sudeep Pharma share price target for FY27 to FY28 is Rs 1,200 in the bull case, requiring full earnings delivery, re-rating among peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Sudeep Pharma in 2026

Bull Case Sudeep Pharma Share Price Target: Rs 1,200

The bull case Sudeep Pharma share price target of Rs 1,200 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 837.8, this represents approximately 45 percent potential upside.

Bear Case Sudeep Pharma Share Price Target: Rs 670

The bear case Sudeep Pharma share price target of Rs 670 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 581.

Scenario	Target	Key Conditions
Bull Case	Rs 1,200	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 1,000	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 670	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Sudeep Pharma 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Sudeep Pharma share price target of Rs 1,000, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,000 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical Formulations Peers

Intensifying competition from peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals could compress Sudeep Pharma’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,000 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Sudeep Pharma

Check the Univest Screener for live data

Before considering any investment based on the Sudeep Pharma share price target of Rs 1,000, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Sudeep Pharma (NSE: SUDEEPPHRM) with full regulatory protection. Study the competitive landscape among peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals before executing any position.

Plan your entry using the 52 week low of Rs 581 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,000 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Sudeep Pharma’s live share price and receive daily stock recommendations.

Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.

FAQs on Sudeep Pharma Share Price Target 2026

What is the Sudeep Pharma share price target for 2026?

Ans. The Sudeep Pharma share price target 2026 is Rs 1,000, implying approximately 20 percent upside from CMP Rs 837.8. Bull case is Rs 1,200, bear case is Rs 670.

What was the Sudeep Pharma share price target for 2025?

Ans. The 2025 price objective for Sudeep Pharma was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,000, reflecting FY27 growth potential from CMP Rs 837.8.

Is Sudeep Pharma a good investment at Rs 837.8?

Ans. At Rs 837.8, Sudeep Pharma offers potential upside toward Rs 1,000 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Sudeep Pharma share price target 2026?

Ans. Key risks to the Sudeep Pharma share price target of Rs 1,000 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations. Monitoring quarterly results is essential.

What is the 52 week high and low of Sudeep Pharma?

Ans. The 52 week high of Sudeep Pharma is Rs 1,376 and the 52 week low is Rs 581. At CMP Rs 837.8, the stock offers potential upside toward the Rs 1,000 price objective.

What are the main growth catalysts for Sudeep Pharma in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Sudeep Pharma compare to its peers?

Ans. Sudeep Pharma operates in Pharmaceutical Formulations alongside peers in pharma formulations like Anuh Pharma and Lincoln Pharmaceuticals. At CMP Rs 837.8 with MCap Rs 4,189 crore, it is a potential re-rating candidate toward the Sudeep Pharma share price target of Rs 1,000 on FY27 delivery.

What is the Sudeep Pharma share price target for 2027?

Ans. The long-term Sudeep Pharma share price target for FY27 to FY28 is Rs 1,200 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.